UW-GCRC PROPOSAL REVIEW COMMITTEE MEETING
Project # Principal Investigator
Title (link to full document)
Abbreviated Version
01-225-29 George Wilding, M.D. Laboratory
Correlates of Angiogenesis
(****)
(SPID 0123) Inhibition
in Patients Receiving
2-Methoxyestradiol
(CO 00809)
01-785-09 Dale A. Schoeller, Ph.D. Validation
of Deuterium Labeled Fatty Acids (****)
(SPID 0124) for
the Measurement of Dietary Fat Oxidation
During
Physical Exercise
01-900-03 Sharon M. Bartosh, M.D.
An
Open-Label, Two Parallel Age Cohort, (****)
(SPID 0125)
Single
Oral Dose Study to Assess the Pharmaco-
kinetics
of Entric-Coated ERL080 180 mg Tablets
in
Stable Renal Transplant Recipients
01-770-07 Minesh P. Mehta, M.D.
Phase
II Evaluation of Fenretinide as a Single
(****)
(SPID 0126)
Agent
Treatment of Adult Patients with Recurrent
Malignant
Glioma (NABTC 9905)
01-655-11 James A. Stewart, M.D.
Phase
III Trial of High Dose Interferon Alpha-2b (****)
(SPID 0127)
Versus
Cisplatin, Vinblastine, DTIC Plus
Interleukin-2
and Interferon in Patients with
High-Risk
Melanoma (ECOG S0008)
01-770-10 Minesh P. Mehta, M.D. An
Open Label, Phase II Trial to Evaluate the (****)
(SPID 0128) Safety
and Pharmacokinetics of Motexafin
Gadolinium
and Cranial Irradiation in the Treatment
of
Newly Diagnosed Glioblastoma Multiforme (RO 00322)
01-225-31 George Wilding, M.D. A
Phase I and Pharmacodynamic Study of (****)
(SPID 0129) Proteasome
Inhibitor PS-341 in Combination with
Doxorubicin
in Patients with Advanced Solid
Tumors
(CO 01901)
01-965-01 Kenneth B. DeSantes, M.D. Phase
I/II Trial of De-escalation of Busulfin with (****)
(SPID 0130) Fludarabin
and Antithymocyte Globulin as Therapy
for
Hematopoietic Stem Cell Transplant for the Treatment
of
Severe Congenital T-Cell Immunodeficiency.
01-970-01 Mark A. Sager, M.D. Wisconsin
Registry for Alzheimer's Prevention. (****)
(SPID 0131)
[ HOME ]
copyright 1999,2000 University of Wisconsin-Madison Medical School
